|Mr. Michael Wolff Jensen L.L.M.||Chairman, Sr. VP, Gen. Counsel and Member of Exec. Board||N/A||N/A||1971|
|Mr. Jan Møller Mikkelsen||Chief Exec. Officer, Pres, Member of Exec. Board and Exec. Director||N/A||N/A||1960|
|Mr. Scott T. Smith||Chief Financial Officer and Sr. VP||N/A||N/A||1974|
|Mrs. Lotte Sønderbjerg||Chief Admin. Officer, Sr. VP and Member of Exec. Board||N/A||N/A||1961|
|Dr. Grethe Rasmussen Ph.D.||Sr. VP of Product Devel. and Member of Exec. Board||N/A||N/A||1962|
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.